A study published today, Friday, showed that a possible vaccine to treat the Coronas SARS-Cove-2 virus had at least partial efficacy in human tests.
According to a study by the Beijing Institute of Biotechnology, published in The Lancet medical journal, the active substance "A5-In Cove" has proven to be safe and well tolerated in the so-called first-stage experience.
The authors of the study wrote that the substance, "AD5, directed to the Covid-19 vaccine, is tolerable and immune for 28 days after vaccination."
The study showed that it causes an immune response to the SARS-Cove-2 virus in the human body.
It is harmful to do further tests to see if this reaction will also prevent infection with the virus.
"These results represent an important stage," said Professor Wei Chen, who is in charge of studying in Beijing.
He added that a single dose of the "A5-N Cove" was sufficient to produce neutral and specific antibiotics for the virus, and the equivalent of the reaction of special defensive cells (T cells) in the test subjects within 14 days.
He nevertheless recommended that this be interpreted "with caution".